Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

DHR vs TMO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
DHR
Danaher Corporation

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$123.80B
5Y Perf.+18.4%
TMO
Thermo Fisher Scientific Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$175.76B
5Y Perf.+35.4%

DHR vs TMO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
DHR logoDHR
TMO logoTMO
IndustryMedical - Diagnostics & ResearchMedical - Diagnostics & Research
Market Cap$123.80B$175.76B
Revenue (TTM)$24.78B$45.20B
Net Income (TTM)$3.69B$6.86B
Gross Margin60.7%39.4%
Operating Margin21.0%17.8%
Forward P/E20.7x19.0x
Total Debt$18.42B$40.85B
Cash & Equiv.$4.62B$9.86B

DHR vs TMOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

DHR
TMO
StockMay 20May 26Return
Danaher Corporation (DHR)100118.4+18.4%
Thermo Fisher Scien… (TMO)100135.4+35.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: DHR vs TMO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: TMO leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Danaher Corporation is the stronger pick specifically for capital preservation and lower volatility and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
DHR
Danaher Corporation
The Income Pick

DHR is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • Dividend streak 1 yrs, beta 0.94, yield 0.7%
  • Lower volatility, beta 0.94, Low D/E 35.1%, current ratio 1.87x
  • Beta 0.94, yield 0.7%, current ratio 1.87x
Best for: income & stability and sleep-well-at-night
TMO
Thermo Fisher Scientific Inc.
The Growth Play

TMO carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 3.9%, EPS growth 7.3%, 3Y rev CAGR -0.3%
  • 229.1% 10Y total return vs DHR's 218.0%
  • PEG 9.02 vs DHR's 34.20
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthTMO logoTMO3.9% revenue growth vs DHR's 2.9%
ValueTMO logoTMOLower P/E (19.0x vs 20.7x), PEG 9.02 vs 34.20
Quality / MarginsTMO logoTMO15.2% margin vs DHR's 14.9%
Stability / SafetyDHR logoDHRBeta 0.94 vs TMO's 1.10, lower leverage
DividendsDHR logoDHR0.7% yield, 1-year raise streak, vs TMO's 0.4%
Momentum (1Y)TMO logoTMO+16.6% vs DHR's -7.2%
Efficiency (ROA)TMO logoTMO6.4% ROA vs DHR's 4.5%, ROIC 7.5% vs 5.9%

DHR vs TMO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

DHRDanaher Corporation
FY 2025
Revenue from Contract with Customer, Measurement, Recurring
81.9%$20.1B
Revenue from Contract with Customer, Measurement, Nonrecurring
18.1%$4.4B
TMOThermo Fisher Scientific Inc.
FY 2025
Consumables
41.9%$18.7B
Service
41.7%$18.6B
Instruments
16.4%$7.3B

DHR vs TMO — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLTMOLAGGINGDHR

Income & Cash Flow (Last 12 Months)

Evenly matched — DHR and TMO each lead in 3 of 6 comparable metrics.

TMO is the larger business by revenue, generating $45.2B annually — 1.8x DHR's $24.8B. Profitability is closely matched — net margins range from 15.2% (TMO) to 14.9% (DHR).

MetricDHR logoDHRDanaher Corporati…TMO logoTMOThermo Fisher Sci…
RevenueTrailing 12 months$24.8B$45.2B
EBITDAEarnings before interest/tax$7.2B$10.5B
Net IncomeAfter-tax profit$3.7B$6.9B
Free Cash FlowCash after capex$5.3B$6.7B
Gross MarginGross profit ÷ Revenue+60.7%+39.4%
Operating MarginEBIT ÷ Revenue+21.0%+17.8%
Net MarginNet income ÷ Revenue+14.9%+15.2%
FCF MarginFCF ÷ Revenue+21.4%+14.9%
Rev. Growth (YoY)Latest quarter vs prior year+3.7%+6.2%
EPS Growth (YoY)Latest quarter vs prior year+9.8%+11.3%
Evenly matched — DHR and TMO each lead in 3 of 6 comparable metrics.

Valuation Metrics

TMO leads this category, winning 4 of 7 comparable metrics.

At 26.7x trailing earnings, TMO trades at a 23% valuation discount to DHR's 34.7x P/E. Adjusting for growth (PEG ratio), TMO offers better value at 12.62x vs DHR's 34.20x — a lower PEG means you pay less per unit of expected earnings growth.

MetricDHR logoDHRDanaher Corporati…TMO logoTMOThermo Fisher Sci…
Market CapShares × price$123.8B$175.8B
Enterprise ValueMkt cap + debt − cash$137.6B$206.8B
Trailing P/EPrice ÷ TTM EPS34.71x26.66x
Forward P/EPrice ÷ next-FY EPS est.20.73x19.04x
PEG RatioP/E ÷ EPS growth rate34.20x12.62x
EV / EBITDAEnterprise value multiple18.14x18.99x
Price / SalesMarket cap ÷ Revenue5.04x3.94x
Price / BookPrice ÷ Book value/share2.37x3.33x
Price / FCFMarket cap ÷ FCF23.54x27.93x
TMO leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

DHR leads this category, winning 5 of 9 comparable metrics.

TMO delivers a 13.2% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $7 for DHR. DHR carries lower financial leverage with a 0.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to TMO's 0.76x. On the Piotroski fundamental quality scale (0–9), DHR scores 7/9 vs TMO's 6/9, reflecting strong financial health.

MetricDHR logoDHRDanaher Corporati…TMO logoTMOThermo Fisher Sci…
ROE (TTM)Return on equity+7.1%+13.2%
ROA (TTM)Return on assets+4.5%+6.4%
ROICReturn on invested capital+5.9%+7.5%
ROCEReturn on capital employed+7.0%+9.1%
Piotroski ScoreFundamental quality 0–976
Debt / EquityFinancial leverage0.35x0.76x
Net DebtTotal debt minus cash$13.8B$31.0B
Cash & Equiv.Liquid assets$4.6B$9.9B
Total DebtShort + long-term debt$18.4B$40.9B
Interest CoverageEBIT ÷ Interest expense18.13x5.89x
DHR leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

TMO leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in TMO five years ago would be worth $10,211 today (with dividends reinvested), compared to $7,907 for DHR. Over the past 12 months, TMO leads with a +16.6% total return vs DHR's -7.2%. The 3-year compound annual growth rate (CAGR) favors TMO at -4.2% vs DHR's -5.6% — a key indicator of consistent wealth creation.

MetricDHR logoDHRDanaher Corporati…TMO logoTMOThermo Fisher Sci…
YTD ReturnYear-to-date-23.9%-20.1%
1-Year ReturnPast 12 months-7.2%+16.6%
3-Year ReturnCumulative with dividends-15.9%-11.9%
5-Year ReturnCumulative with dividends-20.9%+2.1%
10-Year ReturnCumulative with dividends+218.0%+229.1%
CAGR (3Y)Annualised 3-year return-5.6%-4.2%
TMO leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — DHR and TMO each lead in 1 of 2 comparable metrics.

DHR is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than TMO's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.

MetricDHR logoDHRDanaher Corporati…TMO logoTMOThermo Fisher Sci…
Beta (5Y)Sensitivity to S&P 5000.94x1.10x
52-Week HighHighest price in past year$242.80$643.99
52-Week LowLowest price in past year$172.06$385.46
% of 52W HighCurrent price vs 52-week peak+72.0%+73.4%
RSI (14)Momentum oscillator 0–10032.339.8
Avg Volume (50D)Average daily shares traded4.1M1.9M
Evenly matched — DHR and TMO each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — DHR and TMO each lead in 1 of 2 comparable metrics.

Wall Street rates DHR as "Buy" and TMO as "Buy". Consensus price targets imply 41.2% upside for DHR (target: $247) vs 38.4% for TMO (target: $655). For income investors, DHR offers the higher dividend yield at 0.71% vs TMO's 0.36%.

MetricDHR logoDHRDanaher Corporati…TMO logoTMOThermo Fisher Sci…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$247.00$654.67
# AnalystsCovering analysts4242
Dividend YieldAnnual dividend ÷ price+0.7%+0.4%
Dividend StreakConsecutive years of raises18
Dividend / ShareAnnual DPS$1.23$1.69
Buyback YieldShare repurchases ÷ mkt cap+2.5%+1.7%
Evenly matched — DHR and TMO each lead in 1 of 2 comparable metrics.
Key Takeaway

TMO leads in 2 of 6 categories (Valuation Metrics, Total Returns). DHR leads in 1 (Profitability & Efficiency). 3 tied.

Best OverallThermo Fisher Scientific In… (TMO)Leads 2 of 6 categories
Loading custom metrics...

DHR vs TMO: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is DHR or TMO a better buy right now?

For growth investors, Thermo Fisher Scientific Inc.

(TMO) is the stronger pick with 3. 9% revenue growth year-over-year, versus 2. 9% for Danaher Corporation (DHR). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate Danaher Corporation (DHR) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — DHR or TMO?

On trailing P/E, Thermo Fisher Scientific Inc.

(TMO) is the cheapest at 26. 7x versus Danaher Corporation at 34. 7x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 19. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Thermo Fisher Scientific Inc. wins at 9. 02x versus Danaher Corporation's 34. 20x.

03

Which is the better long-term investment — DHR or TMO?

Over the past 5 years, Thermo Fisher Scientific Inc.

(TMO) delivered a total return of +2. 1%, compared to -20. 9% for Danaher Corporation (DHR). Over 10 years, the gap is even starker: TMO returned +229. 1% versus DHR's +218. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — DHR or TMO?

By beta (market sensitivity over 5 years), Danaher Corporation (DHR) is the lower-risk stock at 0.

94β versus Thermo Fisher Scientific Inc. 's 1. 10β — meaning TMO is approximately 17% more volatile than DHR relative to the S&P 500. On balance sheet safety, Danaher Corporation (DHR) carries a lower debt/equity ratio of 35% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — DHR or TMO?

By revenue growth (latest reported year), Thermo Fisher Scientific Inc.

(TMO) is pulling ahead at 3. 9% versus 2. 9% for Danaher Corporation (DHR). On earnings-per-share growth, the picture is similar: Thermo Fisher Scientific Inc. grew EPS 7. 3% year-over-year, compared to -4. 7% for Danaher Corporation. Over a 3-year CAGR, TMO leads at -0. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — DHR or TMO?

Thermo Fisher Scientific Inc.

(TMO) is the more profitable company, earning 15. 1% net margin versus 14. 7% for Danaher Corporation — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DHR leads at 20. 9% versus 18. 2% for TMO. At the gross margin level — before operating expenses — DHR leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is DHR or TMO more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Thermo Fisher Scientific Inc. (TMO) is the more undervalued stock at a PEG of 9. 02x versus Danaher Corporation's 34. 20x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 19. 0x forward P/E versus 20. 7x for Danaher Corporation — 1. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 41. 2% to $247. 00.

08

Which pays a better dividend — DHR or TMO?

All stocks in this comparison pay dividends.

Danaher Corporation (DHR) offers the highest yield at 0. 7%, versus 0. 4% for Thermo Fisher Scientific Inc. (TMO).

09

Is DHR or TMO better for a retirement portfolio?

For long-horizon retirement investors, Danaher Corporation (DHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

94), 0. 7% yield, +218. 0% 10Y return). Both have compounded well over 10 years (DHR: +218. 0%, TMO: +229. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between DHR and TMO?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

DHR pays a dividend while TMO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

DHR

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 8%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

TMO

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 9%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform DHR and TMO on the metrics below

Revenue Growth>
%
(DHR: 3.7% · TMO: 6.2%)
Net Margin>
%
(DHR: 14.9% · TMO: 15.2%)
P/E Ratio<
x
(DHR: 34.7x · TMO: 26.7x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.